Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patient preference between darolutamide (ODM-201) and enzalutamide in metastatic castration-resistant prostate cancer
2017-001606-14Phase 2Completed
- Sponsor
- Gustave Roussy
- Start
- Oct 2017
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of darolutamide and enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Gustave Roussy. Primary endpoint: Patient preference between darolutamide and enzalutamide. Started Oct 2017; status: completed.
02
Drugs
darolutamideenzalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2017-001606-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001606-14.